Here is more information on clinical trials enrolling patients at UNMC.
Hani Haider, Ph.D., orthopaedic surgery, has received a contract for laboratory testing of specially coated total knee replacement systems.
Ming-Fong Lin, Ph.D., biochemistry & molecular biology, has received an NIH subcontract through Creighton University for his work in defining the role of P-Rex1 in the progression and metastasis of prostate cancer.
Daniel Anderson, M.D., Ph.D., internal medicine-cardiology, has received an NIH subcontract through Brigham & Women’s Hospital. Dr. Anderson will serve as the UNMC lead on this multi-center clinical trial to evaluate whether inhibiting inflammation will lower vascular event (myocardial infarction, stroke or cardiovascular death) rates in patients with stable cardiovascular disease.
Thomas Porter, M.D., internal medicine-cardiology, has received a subcontract from the University of Pittsburgh to evaluate microbubble technology as a possible mechanism to enhance microvascular perfusion when used in combination with ultrasound.
Diana Do, M.D., ophthalmology and visual sciences, will lead a Phase II clinical trial to evaluate the safety and effectiveness of a humanized anti-lipid antibody for the treatment of wet age-related macular degeneration either alone or in combination with conventional treatment.
Whitney Goldner, M.D., internal medicine-DEM, will lead a Phase III clinical trial to evaluate the effectiveness, safety and tolerability of a kinase inhibitor for the treatment of differentiated thyroid cancer in patients who have refractory disease or are unsuitable candidates for radioiodine therapy. This study is currently recruiting patients.
William Rizzo, M.D., pediatrics-metabolism, will lead a Phase III clinical trial to evaluate the safety and effectiveness of an injectable enzyme replacement therapy for the treatment of phenylketonuria (PKU) and the ability of adults to administer the therapy themselves.
Daniel Surdell, M.D., surgery-neurosurgery, will lead a Phase II clinical trial using a new therapeutic agent for the treatment of patients with acute spinal cord injury.
R. Greg Bociek, M.D., internal medicine-oncology/hematology, will lead a Phase III clinical trial to evaluate the effectiveness of a new inhibitor of PI3 delta which is expressed in the white blood cells involved in some hematological cancers. This study is currently recruiting patients with indolent non-Hodgkin lymphoma.
Steven Hinrichs, M.D., pathology & microbiology, is evaluating an automated diagnostic system with conventional manual microscopy.
Lori Maness-Harris, M.D., internal medicine-oncology/hematology, will lead a Phase II clinical trial to evaluate the effectiveness of a chemotherapeutic agent currently used in hematological disorders for the treatment of acute myeloid leukemia. This study is currently recruiting patients.
Mojtaba Akhtari, M.D., internal medicine-oncology/hematology, will lead a Phase III clinical trial to evaluate the effectiveness of a new kinase inhibitor of JAK2 on the treatment of myelofibrosis compared to the current best available therapy.
Christopher Kratochvil, M.D., psychiatry, will lead a Phase IV clinical trial of a longer-lasting, less-easily abused, pro-drug for the treatment of ADHD compared with conventional stimulant therapeutics.
John Um, M.D., surgery-cardiovascular surgery, will lead a compassionate use trial to confirm that the Freedom Driver System of artificial hearts is suitable and that patients and lay caregivers can be trained to manage it outside of the hospital setting.
Deepak Madhavan, M.D., neurological sciences, will lead a Phase III clinical trial of a new compound for the treatment of a variety of neurologic disorders including epilepsy, neuropathic pain, and essential tremor.
Carol Toris, Ph.D., ophthalmology and visual sciences, is evaluating the ability of a novel nitric oxide donor compound to lower intraocular pressure.
Charity Evans, M.D., surgery-general surgery, has received a Gold Foundation award to explore the effect of secondary trauma on medical students, residents and physicians caring for the critically ill. The Gold Foundation partners with medical schools and teaching hospitals to infuse humanism into medical training.
Ted Mikuls, M.D., internal medicine-rheumatology, has received a Rheumatology Research Foundation Medical Student Research Preceptor Award. These awards are used to introduce medical students to rheumatology-related research.